Home/Filings/4/0001213900-25-028225
4//SEC Filing

O'Loughlin Steve 4

Accession 0001213900-25-028225

CIK 0001388320other

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 6:20 PM ET

Size

23.4 KB

Accession

0001213900-25-028225

Insider Transaction Report

Form 4
Period: 2025-03-31
O'Loughlin Steve
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-318,8330 total
    Exercise: $23.49Exp: 2028-07-13Common Stock (8,833 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-311,6660 total
    Exercise: $59.70Exp: 2026-04-14Common Stock (1,666 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-3113,3330 total
    Exercise: $6.96Exp: 2029-07-12Common Stock (13,333 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-31256,4380 total
    Exercise: $4.96Exp: 2032-07-01Common Stock (256,438 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-313,3330 total
    Exercise: $53.70Exp: 2025-10-01Common Stock (3,333 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-31253,1230 total
    Exercise: $5.00Exp: 2033-12-28Common Stock (253,123 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-313,3330 total
    Exercise: $41.70Exp: 2027-03-14Common Stock (3,333 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-3159,0660 total
    Exercise: $9.55Exp: 2030-08-12Common Stock (59,066 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-31107,4630 total
    Exercise: $6.07Exp: 2031-09-01Common Stock (107,463 underlying)
Footnotes (1)
  • [F1]Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration.

Issuer

Actinium Pharmaceuticals, Inc.

CIK 0001388320

Entity typeother

Related Parties

1
  • filerCIK 0001615840

Filing Metadata

Form type
4
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 6:20 PM ET
Size
23.4 KB